NEW YORK, July 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals Inc. (OTCQB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the Actinium Pharmaceuticals' clinical programs and platform technology were presented in Vienna, Austria, at a technical meeting at the International Atomic Energy Agency (IAEA). The presentation was delivered by Dr. David Scheinberg, Interim Director of the Sloan-Kettering Institute, research division of the Memorial Sloan-Kettering Cancer Center.
"There is increasing interest in the uses of alpha particle therapy around the world," said Dr. Scheinberg. "We now see scientists, clinicians, isotope manufacturers, government agencies and commercial companies collaborating to enable therapeutic advances of these agents against cancer."
Dr. Scheinberg's presentation focused on Actinium Pharmaceuticals' drug candidates Actimab-A and Bismab for acute myeloid leukemia as well as applications of alpha immunotherapy in treatment of solid cancers. The IAEA meeting at the United Nations headquarters in Vienna, Austria, was a closed workshop entitled "Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy".
About Actimab - A
Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium-225 and bismuth-213. Antibodies are used as high precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells. Actimab-A consists of the Lintuzumab monoclonal antibody and actinium-225.
Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which giv
|SOURCE Actinium Pharmaceuticals|
Copyright©2012 PR Newswire.
All rights reserved